Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL bill

This article was originally published in The Tan Sheet

Executive Summary

House passes revised version of date rape bill (HR 2130) by a 339-2 vote Jan. 31; President Clinton is expected to sign the bill. The legislation, which classifies gamma hydroxybutyric acid (GHB) and gamma butyrolactone (GBL) as controlled substances, is identical to that recently passed by the Senate (1"The Tan Sheet" Nov. 29, 1999, p. 7). Products containing GBL, a chemical precursor of GHB, have been sold as dietary supplements for improved sleep and athletic performance; FDA began attempting to remove such products from the market last January

You may also be interested in...



Dietary Supplement Adverse Events “Mild” 71% Of Time, Lancet Study Finds

Almost 14% of dietary supplement adverse events reported to poison control centers included in an analysis involved children under age 12, according to a study published in the Jan. 11 issue of The Lancet

Dietary Supplement Adverse Events “Mild” 71% Of Time, Lancet Study Finds

Almost 14% of dietary supplement adverse events reported to poison control centers included in an analysis involved children under age 12, according to a study published in the Jan. 11 issue of The Lancet

Dietary Supplement Adverse Events “Mild” 71% Of Time, Lancet Study Finds

Almost 14% of dietary supplement adverse events reported to poison control centers included in an analysis involved children under age 12, according to a study published in the Jan. 11 issue of The Lancet

Topics

UsernamePublicRestriction

Register

PS090836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel